Dorrance Bennett Jr., serving as a director at Campbell’s Co (NYSE:CPB), facilitated the acquisition of the company’s common equity on June 9, 2026, according to a recent Securities and Exchange Commission filing. The aggregate value of these transactions reached $6,435, executed at a unit price of $21.45 per share. This purchase price reflects a distinct premium relative to the stock’s prevailing market value of $19.94, a level that sits in close proximity to the security’s 52-week low of $19.85. Market data indicates that Campbell’s provides a dividend yield of 7.78%, supported by a track record of uninterrupted dividend distributions spanning 56 consecutive years.
The acquisition structure involved indirect purchases distributed across three distinct transactions. A portion of the shares, specifically 100 units, were acquired by an immediate family member residing within the same household as Mr. Bennett Jr. In this capacity, Mr. Bennett Jr. formally disclaims beneficial ownership of these specific shares, retaining interest only to the extent of his pecuniary stake. Further diversification of the acquisition occurred through two separate transactions of 100 shares each, executed via Uniform Transfer to Minors Act accounts established for Mr. Bennett Jr.’s minor son and daughter. Acting in the role of custodian for these accounts, Mr. Bennett Jr. similarly disclaims beneficial ownership of these shares, limiting his interest to pecuniary considerations.
Following the completion of these transactions, Mr. Bennett Jr.’s indirect holdings include 572,410 shares held through the Bennett Dorrance, Jr. Trust. This insider activity intersects with recent corporate financial disclosures from Campbell’s Co. The company’s third-quarter earnings report presented a mixed financial profile. While the firm demonstrated resilience in cost management by exceeding expectations on both gross and operating margins, and reported earnings per share of $0.50, which surpassed consensus estimates by $0.02, top-line performance faced headwinds. Revenue contracted by 4.0%, a decline slightly exceeding the 3.3% drop anticipated by analysts. Despite maintaining its full-year guidance, management indicated an expectation for results to trend toward the lower end of the projected range.
Market reaction to these financial results has prompted adjustments in analyst outlooks. UBS reduced its price target for CPB to $17 from $19, maintaining a Sell rating driven by persistent inflation concerns. Stifel reaffirmed a Hold rating with a $20 price target, while RBC Capital lowered its target to $21 from $23, citing ongoing demand and cost pressures. Stephens maintained an Equal Weight rating with a $21 target, acknowledging mixed results but noting better-than-expected profitability. Bernstein SocGen Group also reduced its price target to $18 from $19, maintaining an Underperform rating and highlighting weaknesses specifically within the soup segment.